Welcome to our dedicated page for Biocorrx SEC filings (Ticker: BICX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioCorRx Inc.'s SEC filings provide detailed information about the company's financial condition, business operations, clinical development programs, and risk factors relevant to investors. As an OTC-traded company, BioCorRx files periodic reports with the Securities and Exchange Commission that offer transparency into its addiction treatment business and pharmaceutical development activities.
Quarterly Reports (Form 10-Q) detail the company's financial performance, including revenues from LUCEMYRA distribution and Beat Addiction program licensing, operating expenses related to clinical development and general operations, and cash position. These reports include management's discussion and analysis (MD&A) sections that provide context for financial results and explain significant developments affecting the business during the reporting period.
Annual Reports (Form 10-K) offer comprehensive overviews of BioCorRx's business model, market opportunity, competitive landscape, regulatory strategy, and intellectual property portfolio. The risk factors sections outline challenges facing the company, including clinical trial uncertainties, regulatory approval risks, commercialization challenges, competition from established pharmaceutical companies, and the financial requirements of drug development programs.
Current Reports (Form 8-K) announce material corporate events such as clinical trial results, regulatory submissions, partnership agreements, grant awards, changes in executive management, and other significant developments requiring prompt disclosure. These filings often contain the most timely information about developments affecting the company's prospects and valuation.
Investors examining BioCorRx filings should pay particular attention to clinical development timelines for BICX104, burn rate and cash runway projections, revenue growth from commercial products, licensing agreement terms, manufacturing relationships, intellectual property protections, and management's strategic priorities. The filings also disclose related party transactions, stock-based compensation, debt obligations, and other financial arrangements that impact shareholder value.
Given the company's stage of development with both commercial products and clinical-stage assets, the filings provide essential context for evaluating the balance between near-term revenue generation and long-term value creation through successful drug development. Understanding the regulatory pathway, clinical trial design, and commercialization strategy for BICX104 requires careful review of the technical and scientific information presented in these regulatory documents.
BioCorRx (BICX) filed its Q3 2025 10‑Q, highlighting its first meaningful product revenue following the Lucemyra asset purchase. Supply and distribution sales reached $635,224 for the quarter and $946,572 year‑to‑date, driving total net sales of $948,362 for the nine months. The company recorded a Q3 net loss attributable to BioCorRx of $1,917,873 and a year‑to‑date loss of $3,992,701, reflecting higher operating expenses as the business scales.
Cash was $287,688 with a working capital deficit of $13,575,951, and management disclosed substantial doubt about the company’s ability to continue as a going concern. Total assets rose to $7,533,473, including intangible assets of $3,011,833 and goodwill of $2,840,400 tied to the US WorldMeds Lucemyra acquisition, while total liabilities were $20,297,768. The company recognized Q3 grant income of $867,130 under NIDA awards and reported a grant receivable of $761,515 and deferred grant revenue of $56,590. Operating expenses increased to $2,580,811 in Q3, including research and development of $1,004,660 and SG&A of $1,145,353, leading to a Q3 operating loss of $1,945,587.
FAQ
What is the current stock price of Biocorrx (BICX)?
What is the market cap of Biocorrx (BICX)?
